Clinical Trial: Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07801820) titled 'Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus' on Aug. 31.

Brief Summary: This is a randomized, double-blind, placebo- and active-controlled, multicenter Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of MWN109 tablets in participants with type 2 diabetes mellitus (T2DM).

Eligible participants will be randomized to receive different dose levels of MWN109 tablets, MWN109-matched placebo, or semaglutide tablets 14 mg (active control), administered once daily for 20 consecutive weeks.

Approximately 240 adults aged 18 to 75 years with type...